Adaptive Biotechnologies Corporation
High affinity T cell receptors and uses thereof

Last updated:

Abstract:

The present disclosure provides TCRs with high or enhanced affinity against various tumor associated antigens (including human Wilms tumor protein 1 (WT 1) epitopes and mesothelin epitopes), T cells expressing such high affinity antigen specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress one or more of these antigens, such as in cancer.

Status:
Grant
Type:

Utility

Filling date:

23 Dec 2016

Issue date:

8 Jun 2021